Azienda Unita Locale Socio Sanitaria N 8 Berica

Research site

Italy Via Del Parco 1, 36071 Arzignano, Italy

4 trials recruiting
Arteriosclerosis · Heart failure with reduced ejection fraction · Psychotic disorder
Adult patients

About Specializations

Azienda Unita Locale Socio Sanitaria N 8 Berica in Arzignano, Italy specialises in clinical trials of conditions such as Arteriosclerosis, Heart failure with reduced ejection fraction, Psychotic disorder, Dementia of the Alzheimer's type with delusions, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Via Del Parco 136071 ArzignanoItaly

Open in maps ↗

Recruiting now: 4 trials
Conditions studied: 6

More sites in Arzignano Italy

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

8 clinical trials

Arteriosclerosis

Recruiting

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Study of laroprovstat (AZD0780) to reduce heart attack, stroke and vascular complications in patients with atherosclerotic cardiovascular disease or high risk of developing it

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:AstraZeneca AB

Contact Research Centre

Arteriosclerosis

Recruiting

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Study of maridebart cafraglutide to reduce cardiovascular problems in overweight or obese patients with atherosclerotic cardiovascular disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Heart failure with reduced ejection fraction

Recruiting

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational

Study of Omecamtiv Mecarbil for Treating Patients with Chronic Heart Failure and Severely Reduced Heart Pumping Ability

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Omecamtiv mecarbil
Sponsor:Cytokinetics Inc.

Contact Research Centre

Psychotic disorder+2

Recruiting

Study on ITI-1284 for Treating Psychosis in Alzheimer's Patients

Investigational

Study on ITI-1284 for Treating Psychosis in Alzheimer's Patients

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:ITI-1284
Sponsor:Intra-Cellular Therapies Inc.

Contact Research Centre

Arteriosclerosis

Not yet recruiting

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

A study to evaluate the effect of muvalaplin on reducing major cardiovascular events in adults with high levels of lipoprotein(a) and atherosclerotic cardiovascular disease.

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Eli Lilly & Co.

Contact Research Centre

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Italy

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Arteriosclerosis

Not recruiting

Investigating Lepodisiran for Reducing Cardiovascular Events in Adults with Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease or at Risk for a First Cardiovascular Event

Investigational

Investigating Lepodisiran for Reducing Cardiovascular Events in Adults with Elevated Lipoprotein(a) and Atherosclerotic Cardiovascular Disease or at Risk for a First Cardiovascular Event

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:LY3819469 sodium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites